Q4 2021 Eris Lifesciences Ltd Earnings Call Transcript
Ladies and gentlemen, good day, and welcome to Eris Lifesciences Q4 FY '21 Results Conference Call. (Operator Instructions) Please note that this conference is being recorded.
I now hand the conference over to Mr. V Krishnakumar, Chief Operating Officer and Executive Director of the company. Thank you, and over to you, sir.
Good afternoon, and welcome to our Q4 conference call. I'm Krishnakumar, and I'm happy to share the highlights of the quarter as well as the entire year with you.
In terms of financial highlights, I'm happy to report that our Q4 stand-alone revenue grew by 11.3% year-on-year to INR 257 crores and our Q4 consolidated revenue grew by 11.9% to INR 278 crores. As per AIOCD, in quarter 4, the Indian pharma market registered a 5.3% growth, bringing up the FY '21 growth to 2.1%. As expected, most of the growth gained from chronic and subchronic therapies, which grew by 7.7% in Q4 and 5.7% when you take overall FY '21. However, the AIOCD data in Q4 showed a growth of 2% for Eris, which was on account of a high base in the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
